13-6　ⓔ文献

  1. Pinal–Fernandez I, Casal–Dominguez M, et al: Immune–mediated necrotizing myopathy. Curr Rheumatol Rep, 2018; 20: 21.

  2. Sarkar K, Weinberg CR, et al: Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. Arthritis Rheum, 2005; 52: 2433–2438.

  3. Muro Y, Sugiura K, et al: Cutaneous manifestations in dermatomyositis: Key clinical and serological features: a comprehensive review. Clin Rev Allergy Immunol, 2016; 51: 293–302.

  4. Katsumata Y, Ridgway WM, et al: Species–specific immune responses generated by histidyl–tRNA synthetase immunization are associated with muscle and lung inflammation. J Autoimmun, 2007; 29: 174–186.

  5. Okiyama N, Hasegawa H, et al: Experimental myositis inducible with transfer of dendritic cells presenting a skeletal muscle C protein–derived CD8 epitope peptide. Int Immunol, 2015; 27: 327–332.

  6. Kaneko Y, Hanaoka H, et al: Distinct arthropathies of the hands in patients with anti–aminoacyl tRNA synthetase antibodies: usefulness of autoantibody profiles in classifying patients. Rheumatology (Oxford), 2014; 53: 1120–1124.

  7. Hoshino K, Muro Y, et al: Anti–MDA5 and anti–TIF1–γ antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford), 2010; 49: 1726–1733.

  8. McHugh NJ, Tansley SL: Autoantibodies in myositis. Nat Rev Rheumatol, 2018; 14: 290–302.

  9. Tanizawa K, Handa T, et al: The prognostic value of HRCT in myositis–associated interstitial lung disease. Respir Med, 2013; 107: 745–752.

  10. Lundberg IE, Tjärnlund A, et al: 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis, 2017; 76: 1955–1964.

  11. Mimori T, Nakashima R, et al: Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep, 2012; 14: 264–274.